The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 07, 2015

Filed:

Aug. 06, 2012
Applicants:

Inhee Lee, Gyeonggi-do, KR;

Doohyeok Pyeon, Gyeonggi-do, KR;

Myounghyeon Shin, Gyeonggi-do, KR;

Jeongun Hwang, Gyeonggi-do, KR;

Changmin Park, Gyeonggi-do, KR;

Sehoan Kim, Gyeonggi-do, KR;

Heeil Chae, Gyeonggi-do, KR;

Soonyoung Moon, Gyeonggi-do, KR;

Soyoun Kim, Gyeonggi-do, KR;

Jaekeol Rhee, Gyeonggi-do, KR;

Inventors:

Inhee Lee, Gyeonggi-do, KR;

Doohyeok Pyeon, Gyeonggi-do, KR;

Myounghyeon Shin, Gyeonggi-do, KR;

Jeongun Hwang, Gyeonggi-do, KR;

Changmin Park, Gyeonggi-do, KR;

Sehoan Kim, Gyeonggi-do, KR;

Heeil Chae, Gyeonggi-do, KR;

Soonyoung Moon, Gyeonggi-do, KR;

Soyoun Kim, Gyeonggi-do, KR;

Jaekeol Rhee, Gyeonggi-do, KR;

Assignee:

Hyundai Pharm Co., Ltd., Cheonan-si, Chungcheongnam-do, KR;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07C 311/29 (2006.01); C07D 213/71 (2006.01); C07D 215/36 (2006.01); C07C 311/20 (2006.01); C07C 311/19 (2006.01); A61K 31/18 (2006.01); C07C 311/13 (2006.01); C07C 311/39 (2006.01);
U.S. Cl.
CPC ...
C07C 311/19 (2013.01); C07C 311/13 (2013.01); C07C 311/20 (2013.01); C07C 311/29 (2013.01); C07C 311/39 (2013.01); C07C 2101/02 (2013.01); C07C 2101/04 (2013.01); C07C 2101/08 (2013.01); C07C 2101/14 (2013.01); C07C 2103/74 (2013.01); A61K 31/18 (2013.01); C07D 213/71 (2013.01); C07D 215/36 (2013.01);
Abstract

Disclosed are a novel compound or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the same for inhibiting human 11-β-hydroxy steroid dehydrogenase type 1 (11β-HSD1). The disclosed compound and the pharmaceutical composition including the same for inhibiting human 11-β-hydroxy steroid dehydrogenase type 1 (11β-HSD1) are excellent in activity and solubility, and is more efficient in formulation and transfer.


Find Patent Forward Citations

Loading…